Aok 11 tender round: stada takes top active ingredients
Corporate News AOK 11 tender round: STADA takes top active ingredients Awards for omeprazole, risperidone, simvastatin and mirtazapine, among others
Bad Vilbel, February 5, 2013 – Following 18 awards in the tenth tender round of the
Allgemeine Ortskrankenkasse (AOK) in the middle of January, Germany's largest
association of statutory health insurance organizations has now once again selected
STADA Group companies for six active ingredients in 38 alloted areas. In the process,
STADA sales companies were awarded the four strongest active ingredients in terms of
sales that were up for tender: omeprazole, risperidone, simvastatin and mirtazapine. These
STADA products will now be available to the approximately 24 million individuals insured by
“The tendered active ingredients that STADA won are among the most commonly needed
medicines in existence”, says Hartmut Retzlaff, Chairman of the Executive Board of STADA
Arzneimittel AG. “We are happy that we can make a significant contribution to the supply of
medicine and therefore to people's health as the only independent generics Group in
Germany. In consideration of the challenging conditions of the German discount agreement
system, that does not go without saying.”
The public health insurance association tendered a total of eight active ingredients each in
eight alloted areas for three contract partners. STADApharm was awarded eight alloted
areas for mirtazapine and omeprazole, five for risperidone, seven for simvastatin and one
alloted area for the active ingredient combination of lisinopril and hydrochlorothiazide.
ALIUD PHARMA was awarded eight areas for the active ingredient combination of losartan
and hydrochlorothiazide as well as one alloted area for simvastatin. The contractual period
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA's
business model focuses on the health care market. At the center of the internationally oriented business
activities are the pharmaceutical and, in particular, the generics market with sustainable growth potentials. As a
Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller
Chairman of the Supervisory Board: Dr. Martin Abend
globally leading generics producer, STADA has a traditionally strong presence in Europe and is the clear
number 3 in Germany. In financial year 2011, STADA achieved Group sales of EUR 1,715.4 million, adjusted
earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 337.2 million and adjusted net
income of EUR 146.6 million. As of June 30, 2012, STADA employed 7,867 people worldwide.
STADA Arzneimittel AG Corporate Communications D-61118 Bad Vilbel Tel.: +49(0) 6101 603-165 Fax: +49(0) 6101 603-506 e-mail: communications@stada.de
Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller
Chairman of the Supervisory Board: Dr. Martin Abend
International Symposium “Root Research and Applications” RootRAP, 2–4 September 2009, Boku – Vienna, Austria Lignification commencement in roots is controlled by the time after elongation completion Institute of plant physiology, Botanical street 35, Moscow 127276, Russia Phone 7(499)2318330, fax 7(495)9778018, e-mail: n.obroucheva@mail.ru Common event is that deceleration of r
globally leading generics producer, STADA has a traditionally strong presence in Europe and is the clear
number 3 in Germany. In financial year 2011, STADA achieved Group sales of EUR 1,715.4 million, adjusted
earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 337.2 million and adjusted net
income of EUR 146.6 million. As of June 30, 2012, STADA employed 7,867 people worldwide.
STADA Arzneimittel AG Corporate Communications D-61118 Bad Vilbel Tel.: +49(0) 6101 603-165 Fax: +49(0) 6101 603-506 e-mail: communications@stada.de
Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller
Chairman of the Supervisory Board: Dr. Martin Abend